Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.

Xilio Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

40% ORR IN HEAVILY PRE-TREATED PATIENTS WITH MSS MCRC WITHOUT LIVER METASTASES AND WITH HIGH PLASMA TUMOR MUTATIONAL BURDEN (TMB)

XILIO THERAPEUTICS ANNOUNCES LATE-BREAKING PHASE 2 DATA FOR VILASTOBART IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

PRECLINICAL DATA SUPPORT BEST-IN-CLASS POTENTIAL OF MASKED T CELL ENGAGER PROGRAMS AND PLATFORM UTILIZING XILIO'S ATACR AND SEECR FORMATS, INCLUDING EFFICIENT MASKING, POTENT ANTI-TUMOR ACTIVITY AND BROAD THERAPEUTIC INDEX PHASE 1 DATA FOR EFARINDODEKIN ALFA, A TUMOR-ACTIVATED IL-12, DEMONSTRATED PROMISING MONOTHERAPY ANTI-TUMOR ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMORS AND GENERALLY WELL-TOLERATED SAFETY PROFILE PHASE 2 DATA FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED ANTI-CTLA-4, SHOW POTENTIAL FOR CTDNA AS AN EARLY PREDICTOR FOR RESPONSE TO TREATMENT WITH VILASTOBART IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH MSS MCRC WALTHAM, MASS., NOV. 07, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED NEW DATA ACROSS ITS PORTFOLIO, INCLUDING PRECLINICAL DATA HIGHLIGHTING THE BEST-IN-CLASS POTENTIAL FOR XILIO'S MASKED T CELL ENGAGER PLATFORM AND PROGRAMS, AS WELL AS PHASE 1 DATA FOR EFARINDODEKIN ALFA, A TUMOR-ACTIVATED IL-12, AND PHASE 2 DATA RELATED TO CIRCULATING TUMOR DNA (CTDNA) FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED ANTI-CTLA-4.

XILIO THERAPEUTICS HIGHLIGHTS PORTFOLIO OF DIFFERENTIATED MASKED IMMUNOTHERAPIES AT SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

WALTHAM, MASS., NOV. 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE NOVEMBER 1, 2025, THE COMPANY GRANTED A NON-QUALIFIED STOCK OPTION TO PURCHASE 5,700 SHARES OF ITS COMMON STOCK TO ONE NEW EMPLOYEE UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

WALTHAM, MASS., OCT. 30, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT IT WILL PRESENT A LATE-BREAKING POSTER PRESENTATION FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED ANTI-CTLA-4, AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, TAKING PLACE FROM NOVEMBER 5-9, 2025 IN NATIONAL HARBOR, MARYLAND.

XILIO THERAPEUTICS TO PRESENT PHASE 2 DATA FOR VILASTOBART HIGHLIGHTING RESPONSE RATE IN PATIENTS WITH MSS MCRC AND HIGH PLASMA TUMOR MUTATIONAL BURDEN AS A LATE-BREAKING PRESENTATION AT SITC 40TH ANNUAL MEETING

WALTHAM, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED MULTIPLE UPCOMING POSTER PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING, TAKING PLACE FROM NOVEMBER 6-9, 2025 AT THE GAYLORD NATIONAL CONVENTION CENTER IN NATIONAL HARBOR, MARYLAND.

XILIO THERAPEUTICS ANNOUNCES UPCOMING PRESENTATIONS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 40TH ANNUAL MEETING

WALTHAM, MASS., OCT. 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE OCTOBER 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 26,000 SHARES OF ITS COMMON STOCK TO THREE NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

PHASE 1 DATA FOR EFARINDODEKIN ALFA (XTX301) DEMONSTRATE PROMISING ANTI-TUMOR ACTIVITY IN PATIENTS WITH ADVANCED SOLID TUMORS ACHIEVEMENT OF MILESTONE EXTENDS ANTICIPATED CASH RUNWAY INTO FIRST QUARTER OF 2027 WALTHAM, MASS., SEPT. 09, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS,INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE INITIATION OF PATIENT DOSING IN PHASE 2 OF AN ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING EFARINDODEKIN ALFA (XTX301), A TUMOR-ACTIVATED IL-12, AS A MONOTHERAPY IN PATIENTS WITH CERTAIN ADVANCED SOLID TUMORS.

XILIO THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 TRIAL FOR EFARINDODEKIN ALFA (XTX301), A TUMOR-ACTIVATED IL-12, AND ACHIEVEMENT OF $17.5 MILLION DEVELOPMENT MILESTONE UNDER EXCLUSIVE LICENSE AGREEMENT WITH GILEAD

ANNOUNCED UPDATED PHASE 2 DATA AT ASCO FOR VILASTOBART, A TUMOR-ACTIVATED, FC-ENHANCED, ANTI-CTLA-4, DEMONSTRATING DEEP AND DURABLE RESPONSES AND A MEANINGFULLY DIFFERENTIATED SAFETY AND TOLERABILITY PROFILE FOR AN ANTI-CTLA-4 COMBINATION THERAPY

XILIO THERAPEUTICS ANNOUNCES PIPELINE AND BUSINESS UPDATES AND SECOND QUARTER 2025FINANCIAL RESULTS

WALTHAM, MASS., AUG. 01, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE AUGUST 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 134,000 SHARES OF ITS COMMON STOCK TO TWO NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

WALTHAM, MASS., JULY 02, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE JULY 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 10,700 SHARES OF ITS COMMON STOCK TO TWO NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDERNASDAQ LISTING RULE 5635(C)(4)

WALTHAM, MASS., JUNE 10, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE APPOINTMENT OF AKINTUNDE (TUNDE) BELLO, PH.D., TO THE COMPANY'S BOARD OF DIRECTORS.

XILIO THERAPEUTICS APPOINTS AKINTUNDE BELLO, PH.D., TO ITS BOARD OF DIRECTORS

TOTAL GROSS PROCEEDS OF UP TO $150.0 MILLION BEFORE THE END OF 2026 IF ALL SERIES B WARRANTS AND SERIES C WARRANTS ARE EXERCISED FOR CASH XILIO MAY ELECT TO CANCEL UNEXERCISED SERIES B OR SERIES C WARRANTS PROPORTIONATELY TO THE AMOUNT OF NON-DILUTIVE CAPITAL RECEIVED, UNDER CERTAIN CIRCUMSTANCES FINANCING CO-LED BY NEW INVESTORS COASTLANDS CAPITAL AND FRAZIER LIFE SCIENCES AND INCLUDED PARTICIPATION FROM GILEAD SCIENCES, INC., LOGOS CAPITAL, SAMSARA BIOCAPITAL AND OTHER NEW AND EXISTING INVESTORS WALTHAM, MASS., JUNE 05, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF PRE-FUNDED WARRANTS AND ACCOMPANYING COMMON STOCK WARRANTS FOR INITIAL GROSS PROCEEDS OF APPROXIMATELY $50.0 MILLION BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OFFERING EXPENSES.

XILIO THERAPEUTICS ANNOUNCES CLOSING OF $50.0 MILLION PUBLIC OFFERING

WALTHAM, MASS., JUNE 03, 2025 (GLOBE NEWSWIRE) -- XILIO THERAPEUTICS, INC. (NASDAQ: XLO), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING TUMOR-ACTIVATED IMMUNO-ONCOLOGY THERAPIES FOR PEOPLE LIVING WITH CANCER, TODAY ANNOUNCED THAT, EFFECTIVE JUNE 1, 2025, THE COMPANY GRANTED NON-QUALIFIED STOCK OPTIONS TO PURCHASE 181,300 SHARES OF ITS COMMON STOCK TO FIVE NEW EMPLOYEES UNDER XILIO THERAPEUTICS' 2022 INDUCEMENT STOCK INCENTIVE PLAN.

Xilio Therapeutics, Inc.

XLO

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Xilio Therapeutics, Inc.

XLO.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

XLO